Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

46.29 -0.97 (-2.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crispr Therapeutics Ag

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
29 30 Next >
Bull Of The Day: Crispr Therapeutics
CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old... 
Via Talk Markets
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?
A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider. 
Via The Motley Fool
The 3 Best Cathie Wood Stocks to Buy in December
Cathie Wood stocks had a great November and are well-positioned to keep performing well, given the favorable macro backdrop. 
Via InvestorPlace
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
The big biotech's shares have been on the rise this year. 
Via The Motley Fool
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y 
Via Benzinga
Exposures Product Safety
Is This News a Setback or a Step Forward for CRISPR Therapeutics?
It's important to look at the news through a long-term lens. 
Via The Motley Fool
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
The Latest Analyst Ratings for CRISPR Therapeutics
Via Benzinga
Stock Market Rally Nears 2023 Highs; AMD, Google Jump On AI Push: Weekly Review
Treasury yields and crude oil came off multimonth lows on Friday's jobs report. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence Fossil Fuels
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
The timing of the cuts is setting off alarm bells, but the situation is under control. 
Via The Motley Fool
Healthcare Gems: 3 Essential Long-Term Stock Picks
Global healthcare spending reached a record $9 trillion in 2020. Catch the ongoing benefits with these three long-term healthcare stock picks. 
Via InvestorPlace
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
Shareholders will do well to prepare themselves for how regulators might react. 
Via The Motley Fool
5 Unstoppable Trends to Invest $1,000 in for 2024
These next-big-thing trends represent some of the most exciting moneymaking opportunities for investors next year. 
Via The Motley Fool
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases. 
Via InvestorPlace
CRISPR Therapeutics' Gene-Edited Oncology Pipeline To Focus On Expanded Use In Autoimmune Diseases
Monday, CRISPR Therapeutics AG (NASDAQ: CRSP) provided an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T  
Via Benzinga
Better Growth Stock: CRISPR Therapeutics vs. Invitae
One of these stocks may be riskier than the other... 
Via The Motley Fool
The Market's Up This Year. Do You Feel Like You Are Winning?
We've also got a look at two stocks worth watching and the popular toys for this holiday season. 
Via The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex shares have soared 400% over the past decade. 
Via The Motley Fool
If You Invested $5,000 in CRISPR Therapeutics in January, This Is How Much You Would Have Today
CRISPR Therapeutics' shares advanced in the double-digits this year. 
Via The Motley Fool
Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now
The one thing these two stocks have in common is tremendous growth prospects. 
Via The Motley Fool
An Important History Lesson for Gene-Editing Investors
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy. 
Via The Motley Fool
5 Top Stocks to Buy Before 2024
These stocks have room to run -- next year and over the long term. 
Via The Motley Fool
Five Best Performing Stocks Of The Top ETF Of November
Most stocks in ARKK’s portfolio delivered strong returns in November. These five led the way. 
Via Talk Markets
Topics ETFs
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
It's not as long a shot as some might think. 
Via The Motley Fool
Looking for Growth? 2 Top Stocks to Buy Hand Over Fist
These stocks offer enormous long-term growth potential. 
Via The Motley Fool
3 Biotech Stocks That Could Be Multibaggers in the Making
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments. 
Via InvestorPlace
Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception
The ARK Innovation ETF (NYSE:ARKK), managed by renowned investor Cathie Wood, has posted remarkable gains in November, making it the fund’s best-performing month since its launch in 2014. 
Via Benzinga
Topics ETFs
Jim Cramer: Buy Shares Of This Personal Computer Giant, Wait For 'A Little Bit Of Pullback'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would not buy CRISPR Therapeutics AG (NASDAQ: CRSP) stock "all the way up here. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.